Home » Novo Nordisk Licenses Global Rights to Potential Haemostasis Therapy
Novo Nordisk Licenses Global Rights to Potential Haemostasis Therapy
Novo Nordisk has entered a global license agreement with French biotechnology company C2X Pharma and the French national institute for health and medical research (Inserm) for thrombin-activable factor X.
prdomain Business Register
prdomain Business Register
Upcoming Events
-
07May
-
14May
-
30May